141 related articles for article (PubMed ID: 2171414)
1. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Lim MC; Tan YO; Chong PY; Cheah JS
Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
[TBL] [Abstract][Full Text] [Related]
2. Complete response of metastatic adrenal cortical carcinoma to o,p'-DDD in a child.
Krzisnik C; Petric G; Jereb B
Pediatr Hematol Oncol; 1988; 5(1):65-9. PubMed ID: 3152953
[No Abstract] [Full Text] [Related]
3. [The effects of o,p'-DDD on human adrenal steroid synthesis].
Ojima M; Saito M; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
[TBL] [Abstract][Full Text] [Related]
4. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Dickstein G; Shechner C; Arad E; Best LA; Nativ O
J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
[TBL] [Abstract][Full Text] [Related]
6. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
[TBL] [Abstract][Full Text] [Related]
7. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
[TBL] [Abstract][Full Text] [Related]
8. [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP'DDD alone].
Remond S; Bardet S; Charbonnel B
Presse Med; 1992 May; 21(18):865. PubMed ID: 1535153
[No Abstract] [Full Text] [Related]
9. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
Huang H; Fojo T
J Clin Endocrinol Metab; 2008 Oct; 93(10):3730-2. PubMed ID: 18842984
[No Abstract] [Full Text] [Related]
11. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
[TBL] [Abstract][Full Text] [Related]
12. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
Seki M; Nomura K; Hirohara D; Kanazawa M; Sawada T; Takasaki K; Demura H
Endocr Relat Cancer; 1999 Dec; 6(4):529-33. PubMed ID: 10730906
[TBL] [Abstract][Full Text] [Related]
13. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
[TBL] [Abstract][Full Text] [Related]
14. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma.
Hague RV; May W; Cullen DR
Clin Endocrinol (Oxf); 1989 Jul; 31(1):51-7. PubMed ID: 2574647
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
[TBL] [Abstract][Full Text] [Related]
16. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
[TBL] [Abstract][Full Text] [Related]
17. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.
Wooten MD; King DK
Cancer; 1993 Dec; 72(11):3145-55. PubMed ID: 8242539
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
Zidan J; Shpendler M; Robinson E
Am J Clin Oncol; 1996 Jun; 19(3):229-31. PubMed ID: 8638530
[TBL] [Abstract][Full Text] [Related]
19. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
Terzolo M; Pia A; Berruti A; Osella G; Alì A; Carbone V; Testa E; Dogliotti L; Angeli A
J Clin Endocrinol Metab; 2000 Jun; 85(6):2234-8. PubMed ID: 10852456
[TBL] [Abstract][Full Text] [Related]
20. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma.
De León DD; Lange BJ; Walterhouse D; Moshang T
J Clin Endocrinol Metab; 2002 Oct; 87(10):4452-6. PubMed ID: 12364417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
